Login to Your Account



Corbus prepares to put anti-inflammatory drug to the test

By Michael Fitzhugh
Staff Writer

Friday, November 21, 2014

Just six months after revealing a $10.3 million private placement to back development of a once-shelved therapy, Corbus Pharmaceuticals Holdings Inc. is preparing to submit an IND application to jump straight into a phase IIa trial of Resunab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription